ResearcherPhilipps University of MarburgActive in the last 2 years

Fabian Eberle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1473-6065; OpenAlex author ID A5013116512. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 3

Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome. Co-author DOI 10.3389/fonc.2026.1710943 ↗
Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Co-author DOI 10.1007/s00066-023-02085-7 ↗
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy. Last author DOI 10.1007/s00066-023-02106-5 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Stefan Lautenschläger · 2 shared papers, 2023 · strength 0.34
- Paper Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabi… DOI 10.1007/s00066-023-02106-5 ↗
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Ahmed Gawish · 1 shared paper, 2026 · strength 0.26
- Paper Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outc… DOI 10.3389/fonc.2026.1710943 ↗
Thomas Held · 1 shared paper, 2026 · strength 0.26
- Paper Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outc… DOI 10.3389/fonc.2026.1710943 ↗
Philipp Lishewski · 1 shared paper, 2026 · strength 0.26
- Paper Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outc… DOI 10.3389/fonc.2026.1710943 ↗
Daniel Habermehl · 1 shared paper, 2026 · strength 0.26
- Paper Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outc… DOI 10.3389/fonc.2026.1710943 ↗
Sophie Dobiasch · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Eleni Gkika · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Matea Pavic · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Thomas Baptist Brunner · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Falk Roeder · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗
Matthias Gückenberger · 1 shared paper, 2023 · strength 0.12
- Paper Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma u… DOI 10.1007/s00066-023-02085-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.